DAC stands for Drug Affinity Complex, a chemical modification added to peptides that dramatically extends how long they stay active in your body. Unmodified peptides break down within minutes, but a DAC-modified peptide can remain active for days or even weeks. The technology was developed by ConjuChem and is most commonly discussed in connection with CJC-1295, a growth hormone-releasing peptide.
How DAC Works
Peptides have a fundamental problem as drugs: they’re fragile. Enzymes in your blood (called peptidases) chew them up quickly, and your kidneys flush them out before they can do much. A peptide injected without any modification might last only 30 minutes in circulation.
DAC solves this by attaching a small chemical “hook” to the peptide. Once injected, that hook latches onto albumin, the most abundant protein in your blood. Albumin is large, long-lived, and constantly recycled by your body. When a peptide hitches a ride on albumin, two things happen: the peptide becomes too large for the kidneys to filter out quickly, and the albumin physically shields the peptide from the enzymes that would normally destroy it. The bond between the DAC component and albumin is covalent, meaning it’s a strong chemical connection rather than a loose attachment.
The result is that a peptide’s circulating half-life can jump from minutes or hours to days or weeks, depending on the specific molecule.
The Three Parts of a DAC Construct
Every DAC-modified peptide has three components. The first is the drug itself, the active peptide responsible for the biological effect. The second is a linker, a short chemical bridge attached to the peptide. The third, at the far end of the linker, is a reactive chemical group (typically a maleimide) that selectively binds to a specific site on albumin. This reactive group targets a free thiol group on albumin, forming the covalent bond that keeps the peptide locked in circulation.
CJC-1295: The Most Common Example
The peptide most people encounter when researching DAC is CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH). CJC-1295 exists in two forms, and the difference between them illustrates exactly what DAC does.
Without DAC, CJC-1295 (sometimes called Mod GRF 1-29) has a half-life of roughly 30 minutes. It triggers a short pulse of growth hormone release, then disappears. With DAC attached, the same peptide has a half-life of 6 to 8 days. That’s a roughly 300-fold increase in how long it remains active.
This difference changes everything about how the peptide is used. The non-DAC version is typically administered daily (often five days per week) to create brief growth hormone pulses. The DAC version only needs to be injected once per week, since it provides sustained stimulation around the clock. Multiple doses of the DAC version also have a cumulative effect, meaning blood levels build over successive weeks.
The Trade-Off With Sustained Stimulation
A longer half-life isn’t automatically better. Your body releases growth hormone in natural pulses, with the largest spike occurring around 1:00 AM during deep sleep. CJC-1295 without DAC mimics this pattern by triggering a sharp, short burst and then clearing out, leaving room for the body’s own rhythm.
CJC-1295 with DAC, by contrast, provides constant low-level stimulation. Some practitioners argue this “GH bleed” effect blunts the body’s natural overnight spike, leading to a flatter and potentially less effective growth hormone profile overall. This is one reason the non-DAC version remains popular despite the inconvenience of daily injections.
Side Effects of DAC-Modified Peptides
The most frequently reported side effects with CJC-1295 DAC are injection site reactions: temporary pain, swelling, and hardness at the injection site, sometimes with localized hives. Beyond injection sites, common complaints include flu-like symptoms, headaches, nausea, irritability, and anxiety.
Because the DAC modification keeps the peptide active for days, any side effects that do occur can also persist longer than they would with a short-acting version. The cumulative dosing effect means that unwanted reactions may intensify over several weeks of use rather than staying consistent.
Regulatory Status
No DAC-modified peptide is currently approved by the FDA. CJC-1295 DAC has no United States Pharmacopeia monograph and is not a component of any FDA-approved drug product. The FDA has specifically recommended against adding CJC-1295 DAC to the list of bulk drug substances that compounding pharmacies can use, citing insufficient evidence to support its safety and efficacy for clinical use.
Despite this, CJC-1295 with and without DAC is widely available through peptide suppliers and anti-aging clinics. The regulatory landscape around compounded peptides has been shifting, with the FDA tightening oversight of several peptide products that were previously available through compounding pharmacies.
DAC vs. Other Half-Life Extension Strategies
DAC is one of several technologies designed to keep peptides alive longer in the bloodstream. PEGylation attaches polyethylene glycol chains to a peptide, increasing its size so the kidneys can’t filter it as quickly. Lipidation adds fatty acid chains that promote binding to albumin’s fatty acid binding sites, which is how semaglutide (the active ingredient in Ozempic and Wegovy) achieves its week-long duration. Direct fusion to albumin or antibody fragments is yet another approach.
What makes DAC distinct is that it forms a direct covalent bond with albumin already circulating in your blood. Rather than attaching a bulky molecule to the peptide before injection, DAC lets the peptide “find” its own albumin carrier after it’s injected. This keeps the injectable dose small while still achieving the dramatic half-life extension that makes weekly dosing possible.